WO2014016857A1 - Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material - Google Patents

Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material Download PDF

Info

Publication number
WO2014016857A1
WO2014016857A1 PCT/IT2013/000196 IT2013000196W WO2014016857A1 WO 2014016857 A1 WO2014016857 A1 WO 2014016857A1 IT 2013000196 W IT2013000196 W IT 2013000196W WO 2014016857 A1 WO2014016857 A1 WO 2014016857A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
amount
solution
polyurethane
diisocyanate
Prior art date
Application number
PCT/IT2013/000196
Other languages
French (fr)
Inventor
Gianluca Ciardelli
Susanna SARTORI
Monica BOFFITO
Piero SERAFINI
Original Assignee
Politecnico Di Torino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politecnico Di Torino filed Critical Politecnico Di Torino
Priority to CA2877096A priority Critical patent/CA2877096A1/en
Priority to BR112015001635A priority patent/BR112015001635A2/en
Priority to EP13756713.7A priority patent/EP2877514A1/en
Priority to KR20157001768A priority patent/KR20150037873A/en
Priority to CN201380038838.3A priority patent/CN104507994A/en
Priority to US14/417,736 priority patent/US20150250889A1/en
Priority to IN16KON2015 priority patent/IN2015KN00016A/en
Priority to RU2015106123A priority patent/RU2015106123A/en
Priority to JP2015523661A priority patent/JP2015524864A/en
Priority to MX2015001035A priority patent/MX2015001035A/en
Publication of WO2014016857A1 publication Critical patent/WO2014016857A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/48—Polyethers
    • C08G18/4833—Polyethers containing oxyethylene units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/30—Low-molecular-weight compounds
    • C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
    • C08G18/3203—Polyhydroxy compounds
    • C08G18/3212—Polyhydroxy compounds containing cycloaliphatic groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/73—Polyisocyanates or polyisothiocyanates acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
    • C08G18/76—Polyisocyanates or polyisothiocyanates cyclic aromatic
    • C08G18/7657—Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings
    • C08G18/7664—Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings containing alkylene polyphenyl groups
    • C08G18/7671—Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings containing alkylene polyphenyl groups containing only one alkylene bisphenyl group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L75/00—Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
    • C08L75/04—Polyurethanes
    • C08L75/08—Polyurethanes from polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Definitions

  • the present invention refers to heat-sensitive aqueous solutions capable of being injected, based on amphiphilic polyurethane, in particular to be used in the bio-medical field.
  • Minimally invasive surgical techniques allow reducing problems connected to traditional interventions, with high hospital costs (long-lasting interventions, prolonged patient stay) and long patient healing times (long rehabilitation periods, high risk of post-surgery complications).
  • the local release of drugs allows minimising the side effects due to drugs themselves.
  • a necessary requirement for systems capable of being injected is being in low-viscosity liquid or gel form, upon injection.
  • Such materials are particularly interesting for regenerative and aesthetic medicine applications, and for the controlled release of drugs, if they form highly viscous gels under physiologic conditions.
  • Similar systems have been obtained mostly through in vivo reticulation or polymerisation procedures. These procedures however have limits connected to the possible use of scarcely biocompatible monomers or reticulating agents. Moreover, some of these reactions are eso-thermal and generate a local temperature increase.
  • Sol-gel systems of the present invention are a promising alternative in the field of regenerating damages tissues (regenerative medicine) and in the controlled release of drugs, since gelling does not occur through reactive processes, but following the variation of surrounding conditions. Such systems are therefore highly bio-compatible and suitable for encapsulating numerous classes of molecules.
  • hydro-gels capable of being injected are promising substrates for tissue engineering, since they have a water content which is comparable with the one of natural tissues, guarantee an efficient mass transfer, are adapted to be easily handled and can be homogeneously additioned with growth factors, cells or drugs.
  • the chemical-physical nature of hydro-gels further guarantees an easy and homogeneous system colonisation by cells and the complete filling of tissue defects, independently from their shape and sizes.
  • a gel is a compound composed of at least two components: one of them (generally a natural or synthetic polymer or a mixture thereof) forms a three-dimensional reticule immersed into a medium composed of the other component (liquid).
  • hydro-gels capable of being injected that find application in tissue engineering can be classified into physical or reversible gels and chemical or irreversible gels.
  • the passage from the solution (sol) state to the gel state occurs by forming weak interactions between the polymeric chains based on hydrophobic interactions, hydrogen bonds, Van der Waals forces or ionic interactions.
  • Physical hydro-gel show ex-vivo a reversible sol-gel transition; a lower transition, which implies the passage from the sol state to the gel state, and an upper transition next to which the gel collapses or shrinks, expelling part or the whole previously absorbed solvent. These transitions can be induced by changes of temperature, ion concentration, solvent composition or of pH. Hydro-gels showing this behaviour are reactive to stimuli, since a change of their state can be induced through variations of conditions of the surrounding environment.
  • Hydro-gels reacting to stimuli are defined as smart, since the sol-gel transition is induced by the physiologic conditions. Such gels, therefore, are spontaneously formed under certain conditions, without requiring the insertion of reticulating agents, which, typically, are toxic and can limit its degradability.
  • the transition can be induced by different stimuli; depending on the type of stimulus inducing the sol-gel transition, hydro-gels can be distinguished in: (i) heat-sensitive hydro-gels, (ii) hydro-gels sensitive to pH, (iii) hydro-gels sensitive to particular analytes, (iv) hydro-gels based on peptides, and (v) hydro-gels based on amphiphilic polymers.
  • an amphiphilic (or amphipatic) polymer is composed of alternate hydrophobic and hydrophylic groups. These molecular characteristics make, in an aqueous solvent, the polymeric chains spontaneously aggregate, giving rise to micelles which expose the hydrophilic groups to the outside, namely towards the aqueous medium, and hydrophobic groups inwards, maximising the interactions between hydrophilic domains and external environment, and maximising interactions between hydrophobic groups and water.
  • every polymeric solution can be characterised by a critical concentration (CGC), starting from which it is possible to observe a transition from the solution state to the gel state and vice versa.
  • CGC critical concentration
  • the CGC usually, is inversely proportional to the molecular weight of the used polymer. Some systems show a separation between solvent and gel over a certain temperature; in this cases, it is a syneresys.
  • heat-sensitive hydro-gels after having established a certain concentration (greater than the CGC), the polymeric solution can be characterised by two temperatures:
  • LCGT Lower Critical Gelation Temperature: temperature next to which the sol-gel transition occurs. For bio-medical applications, this temperature must preferably be around the body one. Below the
  • Modulation of properties of the sol-gel system in order to obtain the phase transition under adequate physiologic conditions and physical properties, can be performed by acting both on the polymer composition, and on the solution composition. It is, for example, possible to act on the hydrophoby of the polymeric material using for example macrometers with different molecular weight, solution concentration, molecular weight of the polymer, the presence of additives additioned to the formulation (salts, such as, for example, NaCl), solvent choice.
  • salts such as, for example, NaCl
  • Biodegradable and non-biodegradable polyurethane have also been examined. Examples of such polyurethane are disclosed in US4822827, US5254662, US5900246, US20060051394. In the bio-medical field, biodegradable polyurethane are a valid alternative to natural polymers due to their excellent mechanical properties, good biocompatibility and processability.
  • Polyurethane are synthesized using, as reagents, a macrodiol, a diisocyanate and possibly a chain extender.
  • reagents a macrodiol, a diisocyanate and possibly a chain extender.
  • the choice of reagents makes characteristics and properties of polyurethane capable of being modulated depending on specifications of a given application.
  • Soft segments are composed of polyols, generally with molecular weights included between 400 and 5000 Da.
  • Hard segments instead, are composed of diisocyanates and possibly chain extenders. These latter ones are usually diols or diamines with low molecular weight.
  • An accurate selection of the chain extender allows providing the polyurethane with suitable characteristics of biodegrading, biomimetism (insertion of aminoacid sequences sensitive to enzymatic degrade, like the Ala-Ala sequence, or adhesion sequences, such as, for example, peptide Arg-Gly- Asp), or inserting functional groups to be used in a second step for functionalising the material ( -BOC serinol).
  • Polyurethane can be in vivo subjects with hydro lytic, enzymatic or oxidative degrade, according to the type of monomers used in their synthesis.
  • Degradable polyurethane can be produced by inserting bonds capable of being hydrolised inside the main polymeric chain.
  • the most common method used for inserting bonds capable of being hydrolised inside the polymeric chain is the one providing for the use, as soft segments, of polyols containing blocks capable of being hydrolised, like polylactides and poly(e-caprolactone).
  • the synthesis of polyurethane for bio-medical applications occurs through a process with one or two stages; this latter one provides for a first step wherein the synthesis of the prepolymer occurs, and during which an excess of diisocyanate is reacted with the polyol.
  • the prepolymer typically has a low molecular weight and the appearance of a very viscous liquid or a low-melting solid.
  • the following reaction of the prepolymer with the chain extender is the second step of the synthesis and allows obtaining the final polymer with a multi-block structure of the (AB)n type.
  • object of the present invention is solving the above prior art problems, by providing an heat-sensitive sol-gel composition capable of being injected based on polyurethane, in particular to be used in the biomedical field, which does not imply polymerisation reactions or reticulations during or after implants, and therefore does not need the addition in vivo of reticulating agents or monomers, which are potentially sensibilising or toxic.
  • Another object of the present invention is providing an heat-sensitive sol-gel composition capable of being injected, based on polyurethane, in particular to be used in the bio-medical field, which does not generate local temperature increases.
  • an object of the present invention is providing an heat- sensitive sol-gel composition capable of being injected, based on polyurethane, in particular to be used in the bio-medical field, which is capable of being injected with minimally invasive injection systems.
  • Another object of the present invention is providing a polyurethane composition, in particular to be used in the bio-medical field, which can be easily packaged as sterile powders to allow its following solubilisation for use, thereby making this operation quick and free from operation complications.
  • an object of the present invention is providing a heat- sensitive sol-gel composition capable of being injected, in particular to be used in the bio-medical field, which shows, together with the verified biocompatibility of polyurethane, the capability of gelling the solutions at temperatures near the physiological one; such gel provides a mechanical support to tissues and organs and at the same time enables their regeneration.
  • Another object of the present invention is providing a heat-sensitive sol-gel composition capable of being injected, based on polyurethane, in particular to be used in the bio-medical field, which can have degrade times comparable with the tissue regeneration and be made functional with bio- active molecules.
  • Another object of the present invention is providing a polyurethane sol-gel composition additioned with one or more drugs, able to release the drug in vivo in a local and/or controlled way.
  • the present invention therefore refers to a heat-sensitive sol-gel composition capable of being injected composed of an aqueous solution of at least one amphiphilic polyurethane, in particular to be used in the biomedical field (namely a polymeric composition which is preferably in solution at ambient temperature and which gelifies, by micellar aggregation under physiologic conditions) synthesized by using as monomers/macromers poly-ethers and aliphatic diisocyanates. It must be noted how the choice of materials composing the composition according to the present invention will always be aimed to having post-implant non-toxic materials and/or in vivo degrade.
  • Polyethylene glycol is often used as hydrophilic block in making co-amphiphilic polymers.
  • PEG is a poly-ether characterised by a complete capability of being mixed in water within a wide range of temperatures and molecular weights. It is a material, which has numerous qualities, such as hydrophilicity and biocompatibility, which make it ideal for biomedical applications.
  • Polyurethane and polyurethane-urea based on polyethylene glycol has amphiphilic properties, which make them a valid choice for developing sol-gel systems, which, by combining biodegradability and injectability characteristics, lend themselves to a minimally invasive insertion and are subjected to a gelling process under physiologic conditions.
  • the composition according to the present invention belongs to the category of physical or reversible gels and is subjected to a temperature-dependent gelling process.
  • polyurethane used in the heat-sensitive sol-gel composition capable of being injected according to the present invention are synthesized using as reagents at least:
  • the block of polyethylene glycol (PEG) has a molecular weight M consult included between 200 and 5000 Da.
  • Q 2 of at least one diisocyanate of the formula OCN-R-NCO, where R is an aliphatic or aliphatic-alicyclic group containing 4 to 26 carbon atoms.
  • diisocyanate is chosen among 1,6-esamethylene diisocyanate, 1,4-butandiisocyanate, 1 ,4-cicloesamethylene diisocyanate or L-lysine-diisocyanate.
  • the polymerisation reaction occurs in an anhydrous environment (typically in an atmosphere of inert gases, like nitrogen, N 2 , or argon Ar).
  • anhydrous environment typically in an atmosphere of inert gases, like nitrogen, N 2 , or argon Ar.
  • such reaction mixture can comprise at least one solvent such as, for example, 1,2-dichloromethane, tetrahydrofuran, N,N-dimethyl- formamide, 1 ,2-dichloroethane.
  • solvents such as, for example, 1,2-dichloromethane, tetrahydrofuran, N,N-dimethyl- formamide, 1 ,2-dichloroethane.
  • Reagents and solvents used in the synthesis should preferably be anhydrous or anhydrided before the polymerisation reaction; the water content is reduced with a suitable method, in order to obtain a percentage of such molecule which is lower than 1% in weight with respect to the reaction mixture. Examples of anhydridification methods are reflow on molecular sieves and distillation.
  • reaction mixture comprises at least one catalyst, for example, tertiary amines (such as diaminocyclooctane) or organo-metallic compounds (such as dibutyl-tin-dilaurate).
  • catalyst for example, tertiary amines (such as diaminocyclooctane) or organo-metallic compounds (such as dibutyl-tin-dilaurate).
  • reaction mixture for the synthesis of polyurethane used in the heat-sensitive sol-gel composition capable of being injected according to the present invention can comprise at least one third amount Q 3 of at least one chain extender containing two hydroxyl or aminic groups.
  • Diols or diamines that can be used as chain extenders, for the synthesis of the polyurethane composition according to the present invention can have various natures; for example, the chain extender can be chosen among:
  • diols or diamines containing aminoacid sequences such as for example peptide adhesion sequences (for example Arg-Gly-Asp), shear sequences (for example Ala- Ala) or cell-penetrating peptides; diols or diamines composed of aminoacid derivatives (such as, for example, ethylic ester of lysine);
  • diols or diamines containing a protected functional group such as, for example, N-BOC serinol
  • cyclic diols or diamines such as, for example, cyclohesane- dimethanol.
  • the percentage in weight of macrodiol in the reaction mixture is included between 20% and 90% in weight (wt);
  • the first amount Q! of macrodiol, the second amount Q 2 of diisocyanate and the third amount Q 3 of chain extender are present in the reaction mixture according to the present invention, in un molar ratio Qi:Q 2 : Q3 which can preferably range between 1:2:1 and 3:8:5.
  • the reaction of the hydroxyl groups (-OH) of the macrodiol with the isocyanate groups (-NCO) of the diisocyanate implies the formation of the urethane group (a suitable ratio between equivalents of the two reagents is necessary for obtaining a isocyanate-terminated reaction product).
  • the polymerisation reaction is possibly performed in solvents, preferably in previously listed organic solvents.
  • the synthesized polyurethane according to the present invention can be used for preparing aqueous solutions: in particular, the polyurethane composition according to the present invention can be solubilized in:
  • saline solution such as, for example, phosphate buffer, PBS
  • glucosyde solution (glucose or dextrose solution);
  • the amount Q 4 of polyurethane present in the polyurethane solution of the present invention is preferably included between 1% and 99% weight//volume (more preferably between 1% and 50%).
  • the polyurethane solution of the present invention can comprise, in addition to the polyurethane component Q 4j at least one fifth amount Q 5 of a natural polymer, such as carbohydrates and/or proteins (for example, ialuronic acid, gelatine, collagen).
  • the fifth amount Q 5 is included between 0% and 99% (more preferably between 1% and 20%) weight/volume, according to the present invention.
  • the polyurethane solution according to the present invention can comprise at least one sixth amount Q 6 of at least one drug or a bioactive molecule, which can therefore be encapsulated in the micellar system and gradually released in vivo, after having injected the composition in human or animal tissues or organs.
  • a sixth amount Q 6 is included between 0% and 30% weight/volume (still more preferably between 0% and 20%).
  • HDI 1,6-esamethylen-diisocyanate
  • CDM ciclohexan-dimethanol
  • pre-polymerisation the first step of the synthesis occurs at the end of the anhydrification.
  • the pre-polymerisation reaction performed at 85°C for 150 minutes, provides for the addition of diisocyanate to the solution of macrodiol in DCE (amount of diisocyanate equal to 22.43% of the amount in weight of macrodiol) and of catalytis amounts of catalyst (dibutyl-tin-dilaurate);
  • the second step of the synthesis occurs at ambient temperature and provides for the addition of the chain extender (amount of extender equal to 9.6% of the amount in weight of macrodiol) to the pre-polymer solution.
  • the extension step lasts for a period of 16 hours, at the end of which the reaction is ended with addition of methanol;
  • the polymer is solubilised in DCE and again precipitated with the addition of a non-solvent (for example petroleum ether). At the end of this second precipitation, decanting/centrifugation of the polymer is performed. The polymer is then separated from the solvent and placed in a vacuum stove at 40°C for at least 12 hours.
  • a non-solvent for example petroleum ether
  • the polyurethane used here is the one whose synthesis is included in stage 1.
  • composition is prepared complying with the following protocol: - 90 mg of gelatin are hot solubilised in 3 ml di PBS
  • the polyurethane used here is the one whose synthesis is included in stage 1.
  • composition is prepared in compliance with the following protocol:
  • gelatine (90 mg) is added to the solution.
  • the polyurethane synthesized according to the present invention have been characterised through:
  • DSC Differential Scan Calorimetric Analysis
  • FTIR Fourier Transform Infrared Spectroscopy
  • Polyurethane synthesized according to the present invention show contact angle values ranging between 40°C and 60°C.
  • the polyurethane according to the present invention is thereby hydrophilic.
  • rheological tests on sol-gel systems according to the present invention have been carried out through a rotary rheometer, to characterise them from the viscosity point of view (at ambient temperature and under physiologic conditions) and to locate the sol-gel transition starting temperature.
  • Strain sweep tests have been carried out first on all composition being studied, in order to correctly choose the distortion to be imposed in all following analyses.
  • Frequency sweep tests have also been performed, to characterise the behaviour of the sol-gel systems depending on the frequency.
  • compositions according to the present invention have a behaviour of the pseudo-plastic type, namely their complex viscosity ⁇ * decreases when the frequency increases, this being also able to be exploited to facilitate injecting the sol-gel compositions by the designed release systems.
  • the temperature ramp tests pointed out that the complex viscosity, as well as the storage and loss modules G' and G", increase with the temperature; this behaviour is aligned with the gelling process due to the temperature increase.
  • the viscosity values at ambient temperature (25°C) resulted variable in the range 0.15 to 2.5 Pa*s; such values make the compositions according to the present invention, easily injectable through the use of commercial devices (such as, for example, insulin-type needles).
  • compositions according to the present invention can find application in numerous fields of the regenerative and aesthetic medicine.
  • the proposed composition in fact, can serve both as filler, and as drug, growth factor and cells vehicle.
  • Such systems are interesting in regenerating numerous tissues, such as, for example, bone, cartilage, miocardium, in addition to micro- and macro-fillers, for cosmetic (dermal fillers) and aesthetic (prostheses) applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Cosmetics (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)

Abstract

A heat-sensitive sol-gel composition capable of being injected is described, composed of an aqueous solution of at least one amphiphilic polyurethane.

Description

HEAT-SENSITIVE AMPHIPHILIC POLYURETHANE AND AQUEOUS SOLUTION CAPABLE OF BEING INJECTED. BASED ON SUCH MATERIAL
The present invention refers to heat-sensitive aqueous solutions capable of being injected, based on amphiphilic polyurethane, in particular to be used in the bio-medical field.
Within regenerative and aesthetic medicine, systems capable of being injected are the ideal solution to perform minimally invasive interventions and for obtaining systems for the local and/or controlled release of drugs. Minimally invasive surgical techniques allow reducing problems connected to traditional interventions, with high hospital costs (long-lasting interventions, prolonged patient stay) and long patient healing times (long rehabilitation periods, high risk of post-surgery complications). The local release of drugs allows minimising the side effects due to drugs themselves.
A necessary requirement for systems capable of being injected is being in low-viscosity liquid or gel form, upon injection. Such materials are particularly interesting for regenerative and aesthetic medicine applications, and for the controlled release of drugs, if they form highly viscous gels under physiologic conditions. Similar systems have been obtained mostly through in vivo reticulation or polymerisation procedures. These procedures however have limits connected to the possible use of scarcely biocompatible monomers or reticulating agents. Moreover, some of these reactions are eso-thermal and generate a local temperature increase.
Moreover, currently marketed systems with local and controlled release have been obtained through injection of polymeric solutions, using organic solvents (Atrigel®). These solvents however are incompatible with the use of some classes of molecules (for example of a proteic nature) which can be denaturated under such conditions.
Sol-gel systems of the present invention are a promising alternative in the field of regenerating damages tissues (regenerative medicine) and in the controlled release of drugs, since gelling does not occur through reactive processes, but following the variation of surrounding conditions. Such systems are therefore highly bio-compatible and suitable for encapsulating numerous classes of molecules. Moreover, hydro-gels capable of being injected are promising substrates for tissue engineering, since they have a water content which is comparable with the one of natural tissues, guarantee an efficient mass transfer, are adapted to be easily handled and can be homogeneously additioned with growth factors, cells or drugs. The chemical-physical nature of hydro-gels further guarantees an easy and homogeneous system colonisation by cells and the complete filling of tissue defects, independently from their shape and sizes. Injectability and gelling in situ, moreover, make the gel formation occur in direct contact with the cells: in this way, a deposit is formed, result of the creation of a network, which can compenetrate cells and proteins of the extra-cellular matrix of the treated tissue. A gel is a compound composed of at least two components: one of them (generally a natural or synthetic polymer or a mixture thereof) forms a three-dimensional reticule immersed into a medium composed of the other component (liquid). Depending on the gelling mechanism upon which they incur, hydro-gels capable of being injected that find application in tissue engineering can be classified into physical or reversible gels and chemical or irreversible gels. In particular, in physical or reversible gels, the passage from the solution (sol) state to the gel state occurs by forming weak interactions between the polymeric chains based on hydrophobic interactions, hydrogen bonds, Van der Waals forces or ionic interactions. Physical hydro-gel show ex-vivo a reversible sol-gel transition; a lower transition, which implies the passage from the sol state to the gel state, and an upper transition next to which the gel collapses or shrinks, expelling part or the whole previously absorbed solvent. These transitions can be induced by changes of temperature, ion concentration, solvent composition or of pH. Hydro-gels showing this behaviour are reactive to stimuli, since a change of their state can be induced through variations of conditions of the surrounding environment. Hydro-gels reacting to stimuli are defined as smart, since the sol-gel transition is induced by the physiologic conditions. Such gels, therefore, are spontaneously formed under certain conditions, without requiring the insertion of reticulating agents, which, typically, are toxic and can limit its degradability. As stated, the transition can be induced by different stimuli; depending on the type of stimulus inducing the sol-gel transition, hydro-gels can be distinguished in: (i) heat-sensitive hydro-gels, (ii) hydro-gels sensitive to pH, (iii) hydro-gels sensitive to particular analytes, (iv) hydro-gels based on peptides, and (v) hydro-gels based on amphiphilic polymers.
As known, an amphiphilic (or amphipatic) polymer is composed of alternate hydrophobic and hydrophylic groups. These molecular characteristics make, in an aqueous solvent, the polymeric chains spontaneously aggregate, giving rise to micelles which expose the hydrophilic groups to the outside, namely towards the aqueous medium, and hydrophobic groups inwards, maximising the interactions between hydrophilic domains and external environment, and maximising interactions between hydrophobic groups and water.
As known, every polymeric solution can be characterised by a critical concentration (CGC), starting from which it is possible to observe a transition from the solution state to the gel state and vice versa. The CGC, usually, is inversely proportional to the molecular weight of the used polymer. Some systems show a separation between solvent and gel over a certain temperature; in this cases, it is a syneresys. As regards heat-sensitive hydro-gels, after having established a certain concentration (greater than the CGC), the polymeric solution can be characterised by two temperatures:
LCGT (Lower Critical Gelation Temperature): temperature next to which the sol-gel transition occurs. For bio-medical applications, this temperature must preferably be around the body one. Below the
LCGT, there are polymeric solutions, above the LCGT, the gel is formed;
- UCGT (Upper Critical Gelation Temperature): temperature at which the inverse gel-sol transition occurs.
After having set a certain concentration, at temperatures lower than LCGT, small-sized micelles are formed, which freely flow in the aqueous medium. Under these conditions, the hydrogen links between hydrophilic segments of the polymeric chain and water are predominant. When increasing the temperature, interactions between hydrophobic segments increase, hydrogen bonds become weaker, and micelle sizes increase due to the hydrophobic bonds being created between the polymeric chains. Provided that hydro-gel concentration is greater than CGC, the application of a further temperature increase, and having exceeded the LCGT, induce the sol-gel transition: micelle sizes grow, the degree of packaging and aggregation among the micelles increases, till a gel is formed. A further temperature increase above the UCGT implies the destruction of micellar structures and the return to the solution state. Modulation of properties of the sol-gel system, in order to obtain the phase transition under adequate physiologic conditions and physical properties, can be performed by acting both on the polymer composition, and on the solution composition. It is, for example, possible to act on the hydrophoby of the polymeric material using for example macrometers with different molecular weight, solution concentration, molecular weight of the polymer, the presence of additives additioned to the formulation (salts, such as, for example, NaCl), solvent choice.
Among polymers used in making hydro-gels for bio-medical applications, those of natural origin (proteins, polysaccharides) have been widely studied, but however do show some problems, among which the risk of transmitting diseases and a quick degrading.
Biodegradable and non-biodegradable polyurethane have also been examined. Examples of such polyurethane are disclosed in US4822827, US5254662, US5900246, US20060051394. In the bio-medical field, biodegradable polyurethane are a valid alternative to natural polymers due to their excellent mechanical properties, good biocompatibility and processability.
Polyurethane are synthesized using, as reagents, a macrodiol, a diisocyanate and possibly a chain extender. The choice of reagents makes characteristics and properties of polyurethane capable of being modulated depending on specifications of a given application.
Soft segments are composed of polyols, generally with molecular weights included between 400 and 5000 Da. Hard segments, instead, are composed of diisocyanates and possibly chain extenders. These latter ones are usually diols or diamines with low molecular weight. An accurate selection of the chain extender allows providing the polyurethane with suitable characteristics of biodegrading, biomimetism (insertion of aminoacid sequences sensitive to enzymatic degrade, like the Ala-Ala sequence, or adhesion sequences, such as, for example, peptide Arg-Gly- Asp), or inserting functional groups to be used in a second step for functionalising the material ( -BOC serinol).
Polyurethane, moreover, can be in vivo subjects with hydro lytic, enzymatic or oxidative degrade, according to the type of monomers used in their synthesis. Degradable polyurethane can be produced by inserting bonds capable of being hydrolised inside the main polymeric chain. The most common method used for inserting bonds capable of being hydrolised inside the polymeric chain is the one providing for the use, as soft segments, of polyols containing blocks capable of being hydrolised, like polylactides and poly(e-caprolactone). Alternatively, it is possible to insert groups capable of being hydrolised inside the polymer through the hard segment, in particular through the use of chain extenders capable of being hydrolised.
The synthesis of polyurethane for bio-medical applications occurs through a process with one or two stages; this latter one provides for a first step wherein the synthesis of the prepolymer occurs, and during which an excess of diisocyanate is reacted with the polyol. The prepolymer typically has a low molecular weight and the appearance of a very viscous liquid or a low-melting solid. The following reaction of the prepolymer with the chain extender is the second step of the synthesis and allows obtaining the final polymer with a multi-block structure of the (AB)n type.
No heat-sensitive polymeric sol-gel compositions based on polyurethane are known, nor their combinations with natural polymers.
Therefore, object of the present invention is solving the above prior art problems, by providing an heat-sensitive sol-gel composition capable of being injected based on polyurethane, in particular to be used in the biomedical field, which does not imply polymerisation reactions or reticulations during or after implants, and therefore does not need the addition in vivo of reticulating agents or monomers, which are potentially sensibilising or toxic.
Another object of the present invention is providing an heat-sensitive sol-gel composition capable of being injected, based on polyurethane, in particular to be used in the bio-medical field, which does not generate local temperature increases. Moreover, an object of the present invention is providing an heat- sensitive sol-gel composition capable of being injected, based on polyurethane, in particular to be used in the bio-medical field, which is capable of being injected with minimally invasive injection systems.
Another object of the present invention is providing a polyurethane composition, in particular to be used in the bio-medical field, which can be easily packaged as sterile powders to allow its following solubilisation for use, thereby making this operation quick and free from operation complications.
Moreover, an object of the present invention is providing a heat- sensitive sol-gel composition capable of being injected, in particular to be used in the bio-medical field, which shows, together with the verified biocompatibility of polyurethane, the capability of gelling the solutions at temperatures near the physiological one; such gel provides a mechanical support to tissues and organs and at the same time enables their regeneration.
Another object of the present invention is providing a heat-sensitive sol-gel composition capable of being injected, based on polyurethane, in particular to be used in the bio-medical field, which can have degrade times comparable with the tissue regeneration and be made functional with bio- active molecules.
Another object of the present invention is providing a polyurethane sol-gel composition additioned with one or more drugs, able to release the drug in vivo in a local and/or controlled way.
The above and other objects and advantages of the invention, as will result from the following description, are obtained with a heat-sensitive sol- gel composition capable of being injected, in particular to be used in the bio-medical field, as claimed in claim 1. Preferred embodiments and non- trivial variations of the present invention are the subject matter of the dependent claims.
It is intended that all enclosed claims are an integral part of the present description.
It will be immediately obvious that numerous variations and modifications (for example related to shape, sizes, arrangements and parts with equivalent functionality) can be made to what is described, without departing from the scope of the invention, as appears from the enclosed claims.
The present invention will be described in more detail by some preferred embodiments thereof, provided as a non-limiting example.
The present invention therefore refers to a heat-sensitive sol-gel composition capable of being injected composed of an aqueous solution of at least one amphiphilic polyurethane, in particular to be used in the biomedical field (namely a polymeric composition which is preferably in solution at ambient temperature and which gelifies, by micellar aggregation under physiologic conditions) synthesized by using as monomers/macromers poly-ethers and aliphatic diisocyanates. It must be noted how the choice of materials composing the composition according to the present invention will always be aimed to having post-implant non-toxic materials and/or in vivo degrade.
Polyethylene glycol (PEG) is often used as hydrophilic block in making co-amphiphilic polymers. PEG is a poly-ether characterised by a complete capability of being mixed in water within a wide range of temperatures and molecular weights. It is a material, which has numerous qualities, such as hydrophilicity and biocompatibility, which make it ideal for biomedical applications. Polyurethane and polyurethane-urea based on polyethylene glycol has amphiphilic properties, which make them a valid choice for developing sol-gel systems, which, by combining biodegradability and injectability characteristics, lend themselves to a minimally invasive insertion and are subjected to a gelling process under physiologic conditions.
As will be described below in more detail, the composition according to the present invention belongs to the category of physical or reversible gels and is subjected to a temperature-dependent gelling process. The temperature increase determined by the passage from the external environment to the physiologic one, therefore, generates the transition from the sol state to the gel state, without needing any other stimulus of a chemical or environmental nature.
In particular, polyurethane used in the heat-sensitive sol-gel composition capable of being injected according to the present invention, are synthesized using as reagents at least:
- a first amount Qi of at least one and maximum two macrodiols containing at least one block composed of polyethylene glycol (PEG), as oligomer or polymer. Preferably, the block of polyethylene glycol (PEG) has a molecular weight M„ included between 200 and 5000 Da. - a second amount Q2 of at least one diisocyanate of the formula OCN-R-NCO, where R is an aliphatic or aliphatic-alicyclic group containing 4 to 26 carbon atoms.
Preferably, diisocyanate is chosen among 1,6-esamethylene diisocyanate, 1,4-butandiisocyanate, 1 ,4-cicloesamethylene diisocyanate or L-lysine-diisocyanate.
Preferably, the polymerisation reaction occurs in an anhydrous environment (typically in an atmosphere of inert gases, like nitrogen, N2, or argon Ar).
Preferably, such reaction mixture can comprise at least one solvent such as, for example, 1,2-dichloromethane, tetrahydrofuran, N,N-dimethyl- formamide, 1 ,2-dichloroethane. It is possible to provide for the use of many solvents, to enable the solubilization of reagents and/or oligomers which are formed during the reaction. Reagents and solvents used in the synthesis should preferably be anhydrous or anhydrided before the polymerisation reaction; the water content is reduced with a suitable method, in order to obtain a percentage of such molecule which is lower than 1% in weight with respect to the reaction mixture. Examples of anhydridification methods are reflow on molecular sieves and distillation.
Preferably, such reaction mixture comprises at least one catalyst, for example, tertiary amines (such as diaminocyclooctane) or organo-metallic compounds (such as dibutyl-tin-dilaurate).
In addition, the reaction mixture for the synthesis of polyurethane used in the heat-sensitive sol-gel composition capable of being injected according to the present invention can comprise at least one third amount Q3 of at least one chain extender containing two hydroxyl or aminic groups.
Diols or diamines that can be used as chain extenders, for the synthesis of the polyurethane composition according to the present invention, can have various natures; for example, the chain extender can be chosen among:
diols or diamines containing aminoacid sequences, such as for example peptide adhesion sequences (for example Arg-Gly-Asp), shear sequences (for example Ala- Ala) or cell-penetrating peptides; diols or diamines composed of aminoacid derivatives (such as, for example, ethylic ester of lysine);
diols or diamines containing a protected functional group (such as, for example, N-BOC serinol);
cyclic diols or diamines (such as, for example, cyclohesane- dimethanol).
Preferably:
the percentage in weight of macrodiol in the reaction mixture is included between 20% and 90% in weight (wt);
percentage in weight of diisocyanate in the reaction mixture is included between 80% and 10% in weight (wt);
- percentage in weight of the chain extender in the reaction mixture ranges between 0% and 65% in weight (wt).
The first amount Q! of macrodiol, the second amount Q2 of diisocyanate and the third amount Q3 of chain extender are present in the reaction mixture according to the present invention, in un molar ratio Qi:Q2: Q3 which can preferably range between 1:2:1 and 3:8:5. The reaction of the hydroxyl groups (-OH) of the macrodiol with the isocyanate groups (-NCO) of the diisocyanate implies the formation of the urethane group (a suitable ratio between equivalents of the two reagents is necessary for obtaining a isocyanate-terminated reaction product). The polymerisation reaction is possibly performed in solvents, preferably in previously listed organic solvents.
Advantageously, the synthesized polyurethane according to the present invention, as described above, can be used for preparing aqueous solutions: in particular, the polyurethane composition according to the present invention can be solubilized in:
- water;
saline solution (such as, for example, phosphate buffer, PBS);
glucosyde solution (glucose or dextrose solution);
gluco-saline solution.
The amount Q4 of polyurethane present in the polyurethane solution of the present invention is preferably included between 1% and 99% weight//volume (more preferably between 1% and 50%).
In addition, the polyurethane solution of the present invention can comprise, in addition to the polyurethane component Q4j at least one fifth amount Q5 of a natural polymer, such as carbohydrates and/or proteins (for example, ialuronic acid, gelatine, collagen). The fifth amount Q5 is included between 0% and 99% (more preferably between 1% and 20%) weight/volume, according to the present invention.
In addition, the polyurethane solution according to the present invention can comprise at least one sixth amount Q6 of at least one drug or a bioactive molecule, which can therefore be encapsulated in the micellar system and gradually released in vivo, after having injected the composition in human or animal tissues or organs. Preferably, such sixth amount Q6 is included between 0% and 30% weight/volume (still more preferably between 0% and 20%).
The following Examples include some typical examples related to preparations stages of the polyurethane solutions of the present invention, as described above.
Stage 1
Herein below, as an example, the synthesis is described of a polyurethane according to the present invention, obtained through a two- step synthesis process. Reagents used in this synthesis are:
- polyethylene glycol (M„ = 1500 g/mol);
1 ,6-esamethylen-diisocyanate (HDI);
- ciclohexan-dimethanol (CDM).
The synthesis process occurred through the following steps:
a) anhydrification of solvent and reagents: with the use of a ball.-type system and two soxhlet, solvent (1,2-dichloroetane -DCE-) and reagents (macrodiol and chain extender) are anhydrided in an inert atmosphere of N2 by reflow on molecular sieves. The operation is performed for 8 hours;
b) pre-polymerisation (first step): the first step of the synthesis occurs at the end of the anhydrification. The pre-polymerisation reaction, performed at 85°C for 150 minutes, provides for the addition of diisocyanate to the solution of macrodiol in DCE (amount of diisocyanate equal to 22.43% of the amount in weight of macrodiol) and of catalytis amounts of catalyst (dibutyl-tin-dilaurate);
c) addition of the chain extender (second step): the second step of the synthesis occurs at ambient temperature and provides for the addition of the chain extender (amount of extender equal to 9.6% of the amount in weight of macrodiol) to the pre-polymer solution. The extension step lasts for a period of 16 hours, at the end of which the reaction is ended with addition of methanol;
d) precipitation and purification: the polymeric solution is added drop- wise to a non-solvent of the polymer (petroleum ether), the system is decanted and the solution separated from the polymer.
The polymer is solubilised in DCE and again precipitated with the addition of a non-solvent (for example petroleum ether). At the end of this second precipitation, decanting/centrifugation of the polymer is performed. The polymer is then separated from the solvent and placed in a vacuum stove at 40°C for at least 12 hours.
Stage 2a
Herein below, as an example, the preparation of a composition according to the present invention is described, with the following composition:
· 10%wt polyurethane;
• 3%wt gelatine (Type B gelatine from cow hide);
• solvent: PBS (system volume: 3 ml).
The polyurethane used here is the one whose synthesis is included in stage 1.
The composition is prepared complying with the following protocol: - 90 mg of gelatin are hot solubilised in 3 ml di PBS
- 0.3 g of polyurethane are added to the previous solution and solubilised.
Stage 2b
Herein below, as an example, the preparation of a formulation according to the present invention is described, having the following composition:
• 10% wt polyurethane;
• 3%wt gelatine (Type B gelatine from cow hide);
• solvent: PBS (system volume: 3 ml);
• adenosine (concentration: 4 mg/ml).
The polyurethane used here is the one whose synthesis is included in stage 1.
The composition is prepared in compliance with the following protocol:
Polyurethane (0,3 g) is solubilised in acetone (10% w/v); drug (adenosine, 12 mg) and PBS are added to the previous solution, in such amounts as to have a volume ratio PBS:acetone = 1 :20;
- the thereby obtained solution is added drop-wise to the PBS volume;
- from the thereby prepared solution acetone is removed;
gelatine (90 mg) is added to the solution.
The polyurethane synthesized according to the present invention, have been characterised through:
- Molecular Exclusion Chromatography (SEC) to determine the mean molecular weight in number (M„) and in weight (Mw): the thereby synthesized polymers result as having Mn included between 10.000 and 25.000 Da;
Differential Scan Calorimetric Analysis (DSC) to measure the thermal properties: objective of this technique is locating the thermal transitions and the crystallinity degree of polyurethane. Polyurethane synthesized according to the present invention have a crystallinity in the range 25-30%;
Fourier Transform Infrared Spectroscopy (FTIR) to analyse the chemical structure. In detail, from the analysis of the FTIR spectrum, it has been possible to identify the characteristic peaks of the urethane ground, which confirm that the synthesis successfully occurred. In particular, the peak around 1710 cm'1 is characteristic of the stretching of free C=0 groups linked to urethane groups. At about l lOOcm'l the stretching of the CH2-0-CH2 group can be observed, characteristic of aliphatic ethers, such as for example PEG. All other peaks, which can be observed on spectra point out a structure in compliance with the forecasts. No peaks related to diisocyanate groups around 2200cm"1 have further been detected, pointing out that the conversion of such groups has been quantitative and that, consequently, the polymerisation process occurred completely;
surface wettability through the static Contact Angle, to evaluate the surface properties. Polyurethane synthesized according to the present invention show contact angle values ranging between 40°C and 60°C. The polyurethane according to the present invention is thereby hydrophilic.
The polyurethane sol-gel compositions according to the present invention have been characterised through:
- Injectability Tests through 2.5-ml graduated syringes and a 20Gauge needle. Injectability tests pointed out that the sol-gel formulation of the present invention can be easily charged inside a syringe and flow without difficulty through a 20Gauge needle;
Rheological Analysis: rheological tests on sol-gel systems according to the present invention have been carried out through a rotary rheometer, to characterise them from the viscosity point of view (at ambient temperature and under physiologic conditions) and to locate the sol-gel transition starting temperature. Strain sweep tests have been carried out first on all composition being studied, in order to correctly choose the distortion to be imposed in all following analyses. Frequency sweep tests have also been performed, to characterise the behaviour of the sol-gel systems depending on the frequency. In particular, these latter tests pointed out that the compositions according to the present invention have a behaviour of the pseudo-plastic type, namely their complex viscosity η* decreases when the frequency increases, this being also able to be exploited to facilitate injecting the sol-gel compositions by the designed release systems. The temperature ramp tests pointed out that the complex viscosity, as well as the storage and loss modules G' and G", increase with the temperature; this behaviour is aligned with the gelling process due to the temperature increase. The viscosity values at ambient temperature (25°C) resulted variable in the range 0.15 to 2.5 Pa*s; such values make the compositions according to the present invention, easily injectable through the use of commercial devices (such as, for example, insulin-type needles). Kinetic tests at 37°C allowed to point out that the compositions according to the present invention remain in the gel phase (G'>G") for the whole time interval taken into account, and that the complex viscosity increases also when the system is kept at constant temperature, demonstrating that the gelling process is not only temperature- dependent, but also time-dependent.
The compositions according to the present invention can find application in numerous fields of the regenerative and aesthetic medicine. The proposed composition, in fact, can serve both as filler, and as drug, growth factor and cells vehicle. Such systems are interesting in regenerating numerous tissues, such as, for example, bone, cartilage, miocardium, in addition to micro- and macro-fillers, for cosmetic (dermal fillers) and aesthetic (prostheses) applications.

Claims

1. Heat-sensitive sol-gel composition capable of being injected composed of an aqueous solution of at least one amphiphilic polyurethane, characterised in that said amphiphilic polyurethane is adapted to be synthesized through a polymerisation reaction mixture comprising at least: a first amount (Qi) of at least one and maximum two macrodiols containing at least one block composed of polyethylene glycol (PEG) in a form of an oligomer or a polymer;
a second amount (Q2) of at least one diisocyanate with formula OCN-R-NCO, where R is an aliphatic group containing 4 to 26 carbon atoms.
2. Composition according to claim 1 , characterised in that said reaction mixture comprises at least one solvent.
3. Composition according to the previous claim, characterised in that said solvent is chosen among 1,2-dichloromethane, tetrahydrofiirane, N,N- dimethylformamide, 1,2-dichloroethane.
4. Composition according to claim 1, characterised in that said reaction mixture comprises at least one catalyst.
5. Composition according to the previous claim, characterised in that said catalyst is chosen among tertiary amines or organ-metallic compounds.
6. Composition according to claim 1, characterised in that said first amount (Q,) of macrodiol is included between 20% and 90% in weight (wt) of said reaction mixture and said second amount (Q2) of diisocyanate is included between 80% and 10% in weight (wt) of said reaction mixture.
7. Composition according to claim 1, characterised in that the molecular weight of said block of polyethylene glycol (PEG) has a Mn included between 200 and 5000 Da.
8. Composition according to claim 1, characterised in that said diisocyanate is chosen between 1,6-esamethylen diisocyanate, 1,4- butandiisocyanate or 1 ,4-cycloesamethylen diisocyanate, L-lysine- diisocyanate.
9. Composition according to claim 1, characterised in that it is a physical or reversible gel.
10. Composition according to claim 1, characterised in that said reaction mixture comprises at least one third amount (Q3) of at least one chain extender containing due hydroxyl or aminic groups.
11. Composition according to claim 10, characterised in that said chain extender is chosen among diols or diamines containing amino-acid sequences, diols or diamines composed of amino-acid derivatives, diols or diamines containing a protected functional group, cyclic diols or diamines.
12. Composition according to claim 10, characterised in that the percentage in weight of said third amount (Q3) of chain extender in said reaction mixture is included between 0% and 65%.
13. Composition according to claim 10, characterised in that said first amount (Q]) of macrodiol, said second amount (Q2) of diisocyanate and said third amount (Q3) of chain extender are present in said mixture in a molar ratio Qi:Q2:Q3 which can range between 1 :2: 1 and 3:8:5.
14. Composition according to claim 1, characterised in that a liquid phase in which said polymer is solubilised is distilled water, or a saline solution, or a glucosed solution, or a gluco-saline solution.
15. Composition according to claim 1, characterised in that the injectable formulation comprises at least one sixth amount (Q6) of at least one drug or a bioactive molecule.
16. Composition according to claim 15, characterised in that said sixth amount (Q6) is included between 0% and 30% weight/volume, more preferably between 0% and 20%, of said solution.
17. Use of a composition according to any one of claims 1 to 16 for tissue regeneration and in aesthetic add prosthetic medicine.
18. Use according to the previous claim, of said composition as filler, or as vehicle of drugs, growth factors or cells.
19. Polyurethane solution comprising at least one composition according to any one of claims 1 to 16, characterised in that it comprises a fourth amount (Q4) of polyurethane, included between 1% and 99%, more preferably between 1% and 50%, in weight/volume of said solution.
20. Solution according to the previous claim, characterised in that it comprises a fifth amount (Q5) of at least one natural polymer and/or carbohydrates and/or proteins.
21. Solution according to the previous claim, characterised in that said natural polymer and/or carbohydrates and/or proteins is chosen among ialuronic acid, gelatine, collagen.
22. Solution according to claim 20, characterised in that said fifth amount (Q5) is included between 0% and 99%, more preferably between 1% and 20% in weight/volume of said solution.
PCT/IT2013/000196 2012-07-27 2013-07-11 Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material WO2014016857A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2877096A CA2877096A1 (en) 2012-07-27 2013-07-11 Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material
BR112015001635A BR112015001635A2 (en) 2012-07-27 2013-07-11 heat-sensitive amphiphilic polyurethane and injectable aqueous solution based on such material
EP13756713.7A EP2877514A1 (en) 2012-07-27 2013-07-11 Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material
KR20157001768A KR20150037873A (en) 2012-07-27 2013-07-11 Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material
CN201380038838.3A CN104507994A (en) 2012-07-27 2013-07-11 Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material
US14/417,736 US20150250889A1 (en) 2012-07-27 2013-07-11 Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material
IN16KON2015 IN2015KN00016A (en) 2012-07-27 2013-07-11
RU2015106123A RU2015106123A (en) 2012-07-27 2013-07-11 THERMOSENSITIVE AMPHIPHILIC POLYURETHANE AND AQUEOUS SOLUTION INJECTED ON THE BASIS OF THIS MATTER
JP2015523661A JP2015524864A (en) 2012-07-27 2013-07-11 Thermosensitive amphiphilic polyurethanes and injectable aqueous solutions based on such materials
MX2015001035A MX2015001035A (en) 2012-07-27 2013-07-11 Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000669A ITTO20120669A1 (en) 2012-07-27 2012-07-27 THERMOSENSITIVE AMPHIFILIAN POLYURETHANE AND AQUEOUS SOLUTION INJECTABLE TO THE BASIS OF SUCH MATERIAL.
ITTO2012A000669 2012-07-27

Publications (1)

Publication Number Publication Date
WO2014016857A1 true WO2014016857A1 (en) 2014-01-30

Family

ID=46982769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2013/000196 WO2014016857A1 (en) 2012-07-27 2013-07-11 Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material

Country Status (13)

Country Link
US (1) US20150250889A1 (en)
EP (1) EP2877514A1 (en)
JP (1) JP2015524864A (en)
KR (1) KR20150037873A (en)
CN (1) CN104507994A (en)
BR (1) BR112015001635A2 (en)
CA (1) CA2877096A1 (en)
CL (1) CL2015000195A1 (en)
IN (1) IN2015KN00016A (en)
IT (1) ITTO20120669A1 (en)
MX (1) MX2015001035A (en)
RU (1) RU2015106123A (en)
WO (1) WO2014016857A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209740A1 (en) 2019-04-12 2020-10-15 Institutul De Chimie Macromoleculară Petru Poni Non-isocyanate polyurethane thermoreversible hydrogel and method for its preparation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110724245A (en) * 2018-07-17 2020-01-24 四川大学 Injectable polyurethane and process for its preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822827A (en) 1987-12-17 1989-04-18 The Dow Chemical Company Thermoplastic polyurethanes with high glass transition temperatures
US5000955A (en) * 1988-07-29 1991-03-19 Tyndale Plains-Hunter Ltd. Thermally reversible polyurethane hydrogels and cosmetic, biological and medical uses
US5254662A (en) 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
US5900246A (en) 1993-03-18 1999-05-04 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
US20060051394A1 (en) 2004-03-24 2006-03-09 Moore Timothy G Biodegradable polyurethane and polyurethane ureas
WO2007117222A1 (en) * 2006-04-12 2007-10-18 Agency For Science, Technology And Research Biodegradable thermogelling polymer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307065B1 (en) * 2008-07-02 2018-02-14 Allergan, Inc. Compositions and methods for tissue filling and regeneration

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822827A (en) 1987-12-17 1989-04-18 The Dow Chemical Company Thermoplastic polyurethanes with high glass transition temperatures
US5000955A (en) * 1988-07-29 1991-03-19 Tyndale Plains-Hunter Ltd. Thermally reversible polyurethane hydrogels and cosmetic, biological and medical uses
US5254662A (en) 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
US5900246A (en) 1993-03-18 1999-05-04 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
US20060051394A1 (en) 2004-03-24 2006-03-09 Moore Timothy G Biodegradable polyurethane and polyurethane ureas
WO2007117222A1 (en) * 2006-04-12 2007-10-18 Agency For Science, Technology And Research Biodegradable thermogelling polymer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANGHONG ZHANG ET AL: "Synthesis and characterization of biocompatible, degradable, light-curable, polyurethane-based elastic hydrogels", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, vol. 82A, no. 3, 23 February 2007 (2007-02-23), pages 637 - 650, XP055046194, ISSN: 1549-3296, DOI: 10.1002/jbm.a.30992 *
LOH X.J. ET AL.: "New Biodegradable Thermogelling Copolymers Having VeryLow Gelation Concentrations", BIOMACROMOLECULES, vol. 8, no. 2, 30 December 2006 (2006-12-30), pages 585 - 593, XP002693045 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209740A1 (en) 2019-04-12 2020-10-15 Institutul De Chimie Macromoleculară Petru Poni Non-isocyanate polyurethane thermoreversible hydrogel and method for its preparation

Also Published As

Publication number Publication date
KR20150037873A (en) 2015-04-08
RU2015106123A (en) 2016-09-20
US20150250889A1 (en) 2015-09-10
JP2015524864A (en) 2015-08-27
BR112015001635A2 (en) 2017-07-04
CL2015000195A1 (en) 2015-05-08
MX2015001035A (en) 2015-06-23
EP2877514A1 (en) 2015-06-03
IN2015KN00016A (en) 2015-07-31
CA2877096A1 (en) 2014-01-30
CN104507994A (en) 2015-04-08
ITTO20120669A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
CN109939065B (en) Medical hydrogel
US7160931B2 (en) Thermally reversible implant and filler
CN101816801B (en) Biomedical foams, preparation thereof and application
CA2632493C (en) Foam control for synthetic adhesive/sealant
AU2006321721B2 (en) Biocompatible surgical compositons
ES2608756T3 (en) Polyurea systems and their application as barriers against postoperative adhesions
EP2783702A1 (en) Water insoluble gel composition and method for preparing same
US8211959B2 (en) Biodegradable copolymer hydrogels
CN102438670B (en) Implant filling material and method
EP1962867A2 (en) Biocompatible surgical compositions
US7193007B2 (en) Environment responsive gelling copolymer
JP2011509713A (en) Bioadhesive hydrogel
EP2291206A2 (en) Polyurethane foam for use in medical implants
WO2015134028A1 (en) Polyurethane foam for use in medical implants
WO2014016857A1 (en) Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material
Jun et al. In situ gel forming stereocomplex composed of four-arm PEG-PDLA and PEG-PLLA block copolymers
NL2027371B1 (en) Injectable cushioning hydrogels
WO2001068768A1 (en) Environment responsive gelling copolymer
CN102731981A (en) Temperature-sensitive injectable mixed hydrogel
CN113143851A (en) Solvent exchange-based injectable hydrogel and preparation method and application thereof
KR101815780B1 (en) Temperature and pH-sensitive hydrogel and the preparing method thereof
US20070110784A1 (en) Thermally reversible implant
CN113461973A (en) Injectable medical hydrogel
CA2551809A1 (en) Implant filling material and method
WO2004096309A1 (en) Thermally reversible implant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13756713

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2877096

Country of ref document: CA

Ref document number: 2015523661

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20157001768

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/001035

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2015000195

Country of ref document: CL

Ref document number: 2013756713

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14417736

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015106123

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015001635

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015001635

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150126